• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 6-K filed by GH Research PLC

    5/8/25 7:18:25 AM ET
    $GHRS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $GHRS alert in real time by email
    false2025-03-3112-31GH Research PLC000185512900100018551292025-01-012025-03-3100018551292024-01-012024-03-3100018551292025-03-3100018551292024-12-310001855129ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember2023-12-310001855129ifrs-full:AdditionalPaidinCapitalMember2023-12-310001855129ifrs-full:IssuedCapitalMember2024-12-310001855129ifrs-full:RetainedEarningsMember2024-12-310001855129ifrs-full:OtherReservesMember2023-12-310001855129ifrs-full:IssuedCapitalMember2023-12-3100018551292023-12-310001855129ifrs-full:RetainedEarningsMember2023-12-310001855129ifrs-full:OtherReservesMember2024-12-310001855129ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember2024-12-310001855129ifrs-full:AdditionalPaidinCapitalMember2024-12-310001855129ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember2025-01-012025-03-310001855129ifrs-full:AdditionalPaidinCapitalMember2025-01-012025-03-310001855129ifrs-full:OtherReservesMember2025-01-012025-03-310001855129ifrs-full:OtherReservesMember2024-01-012024-03-310001855129ifrs-full:IssuedCapitalMember2025-01-012025-03-310001855129ifrs-full:RetainedEarningsMember2024-01-012024-03-310001855129ifrs-full:AdditionalPaidinCapitalMember2024-01-012024-03-310001855129ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember2024-01-012024-03-310001855129ifrs-full:IssuedCapitalMember2024-01-012024-03-310001855129ifrs-full:RetainedEarningsMember2025-01-012025-03-310001855129ifrs-full:IssuedCapitalMember2024-03-310001855129ifrs-full:OtherReservesMember2024-03-3100018551292024-03-310001855129ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember2024-03-310001855129ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember2025-03-310001855129ifrs-full:IssuedCapitalMember2025-03-310001855129ifrs-full:RetainedEarningsMember2025-03-310001855129ifrs-full:AdditionalPaidinCapitalMember2025-03-310001855129ifrs-full:RetainedEarningsMember2024-03-310001855129ifrs-full:OtherReservesMember2025-03-310001855129ifrs-full:AdditionalPaidinCapitalMember2024-03-310001855129ifrs-full:OrdinarySharesMemberghrs:InitialPublicOfferingMember2025-02-062025-02-060001855129ifrs-full:OrdinarySharesMemberghrs:InitialPublicOfferingMember2025-02-060001855129ghrs:FairValueThroughOtherComprehensiveIncomeMember2024-12-310001855129ghrs:FairValueThroughOtherComprehensiveIncomeMember2025-01-012025-03-310001855129ghrs:FairValueThroughOtherComprehensiveIncomeMember2025-03-310001855129ifrs-full:TopOfRangeMember2025-01-012025-03-310001855129ifrs-full:OrdinarySharesMemberghrs:InitialPublicOfferingMember2025-01-012025-02-060001855129ghrs:InitialPublicOfferingMemberifrs-full:OrdinarySharesMember2024-12-310001855129ghrs:InitialPublicOfferingMemberifrs-full:OrdinarySharesMember2025-01-012025-03-310001855129ghrs:InitialPublicOfferingMemberifrs-full:OrdinarySharesMember2025-03-3100018551292021-06-300001855129ifrs-full:ShareOptionsMember2025-03-310001855129ghrs:ShareOptionExpirationPeriodOneMember2025-01-012025-03-310001855129ghrs:ShareOptionExpirationPeriodTwoMember2025-01-012025-03-3100018551292024-01-012024-12-310001855129ifrs-full:TopOfRangeMember2024-01-012024-03-310001855129ifrs-full:BottomOfRangeMember2024-01-012024-03-310001855129ifrs-full:BottomOfRangeMember2025-01-012025-03-310001855129ifrs-full:ReserveOfSharebasedPaymentsMember2024-12-310001855129ifrs-full:ReserveOfSharebasedPaymentsMember2025-03-31iso4217:USDiso4217:USDxbrli:sharesxbrli:sharesxbrli:pureghrs:Segmentutr:Y

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
     
    FORM 6-K
     
    REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER
    THE SECURITIES EXCHANGE ACT OF 1934

    For the month of May, 2025.
     
    Commission File Number: 001-40530

    GH Research PLC
    (Exact name of registrant as specified in its charter)

    Joshua Dawson House
    Dawson Street
    Dublin 2
    D02 RY95
    Ireland
    (Address of principal executive office)

    Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

    Form 20-F
    ☒
     
    Form 40-F
    ☐



    INFORMATION CONTAINED IN THIS REPORT ON FORM 6-K

    On May 8, 2025, GH Research PLC (the “Company”) reported its first quarter 2025 financial results, provided business updates, and made available an updated investor presentation on its website. A copy of the press release is exhibited hereto as Exhibit 99.3 and a copy of the investor presentation is attached hereto as Exhibit 99.4.

    The fact that this press release and investor presentation is being made available and furnished herewith should not be deemed an admission as to the materiality of any information contained in the materials. The information contained in the press release and investor presentation is being provided as of May 8, 2025, and the Company does not undertake any obligation to update the presentation in the future or to update forward-looking statements to reflect subsequent actual results.

    1

    INCORPORATION BY REFERENCE

    This Report on Form 6-K (other than Exhibit 99.3 and Exhibit 99.4 hereto), including Exhibit 99.1 and Exhibit 99.2 hereto, shall be deemed to be incorporated by reference into the registration statement on Form S-8 (Registration Nos. 333-270422 and 333-285311) and the registration statement on Form F-3 (Registration No. 333-285310) of the Company and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished.

    2

    EXHIBIT INDEX

    Exhibit No.
    Description
    99.1
    Unaudited Condensed Consolidated Interim Financial Statements for the three months ended March 31, 2025
    99.2
    Management’s Discussion and Analysis of Financial Condition and Results of Operations
    99.3
    Press release dated May 8, 2025
    99.4
    Corporate Presentation for May 8, 2025
    101.INS
    Inline XBRL Instance Document
    101.SCH
    Inline XBRL Taxonomy Extension Schema Document
    101.CAL
    Inline XBRL Taxonomy Extension Calculation Linkbase Document
    101.DEF
    Inline XBRL Taxonomy Extension Definition Linkbase Document
    101.LAB
    Inline XBRL Taxonomy Extension Label Linkbase Document
    101.PRE
    Inline XBRL Taxonomy Extension Presentation Linkbase Document
    104
    Cover Page Interactive Data File (embedded within the Inline XBRL document)

    3

    SIGNATURE

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

     
    GH Research PLC
    Date: May 8, 2025
     
       
     
    By:
    /s/ Julie Ryan
     
    Name:
    Julie Ryan
     
    Title:
    Vice President, Finance


    4

    Get the next $GHRS alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $GHRS

    DatePrice TargetRatingAnalyst
    6/4/2025$25.00Overweight
    Cantor Fitzgerald
    3/13/2025$32.00Buy
    Guggenheim
    3/7/2025$31.00Outperform
    RBC Capital Mkts
    2/13/2025$14.00Overweight
    Cantor Fitzgerald
    8/16/2022$45.00Buy
    H.C. Wainwright
    6/16/2022$66.00Buy
    ROTH Capital
    7/20/2021Buy
    Stifel
    7/20/2021$35.00Mkt Outperform
    JMP Securities
    More analyst ratings

    $GHRS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by GH Research PLC

      SC 13G/A - GH Research PLC (0001855129) (Subject)

      11/14/24 5:46:11 PM ET
      $GHRS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by GH Research PLC

      SC 13G/A - GH Research PLC (0001855129) (Subject)

      11/14/24 9:05:43 AM ET
      $GHRS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by GH Research PLC

      SC 13G - GH Research PLC (0001855129) (Subject)

      2/16/24 4:57:41 PM ET
      $GHRS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GHRS
    Leadership Updates

    Live Leadership Updates

    See more
    • GH Research Announces Appointment of Dr. Velichka "Villy" Valcheva to Chief Executive Officer

      DUBLIN, Ireland, Sept. 03, 2024 (GLOBE NEWSWIRE) -- GH Research PLC (NASDAQ:GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today announced the promotion of Dr. Velichka "Villy" Valcheva, MD, MSc. to Chief Executive Officer of the Company. Dr. Valcheva succeeds PD Dr. med. Theis Terwey, co-founder of GH Research. Dr. Valcheva has more than 20 years of experience in various leadership roles in the pharmaceutical and biotech industries. Dr. Valcheva joined the company in August 2023 and has served as the Company's Chief Medical Officer since February 2024 having leadership responsibility, among other thin

      9/3/24 7:00:05 AM ET
      $GHRS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • GH Research Reports Second Quarter 2023 Financial Results and Provides Business Updates

      DUBLIN, Ireland, Aug. 23, 2023 (GLOBE NEWSWIRE) -- GH Research PLC (NASDAQ:GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today reported financial results for the second quarter ended June 30, 2023 and provided business updates. Second Quarter 2023 Financial Highlights Cash position Cash, cash equivalents, other financial assets and marketable securities were $238.1 million as of June 30, 2023, compared to cash, cash equivalents and marketable securities of $251.7 million as of December 31, 2022. Cash equivalents and other financial assets comprise money market funds. Marketable securities comprise inv

      8/23/23 7:00:45 AM ET
      $GHRS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GHRS
    SEC Filings

    See more
    • SEC Form 6-K filed by GH Research PLC

      6-K - GH Research PLC (0001855129) (Filer)

      5/27/25 7:00:30 AM ET
      $GHRS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by GH Research PLC

      6-K - GH Research PLC (0001855129) (Filer)

      5/21/25 7:00:41 AM ET
      $GHRS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by GH Research PLC

      SCHEDULE 13G/A - GH Research PLC (0001855129) (Subject)

      5/15/25 4:58:22 PM ET
      $GHRS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GHRS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Cantor Fitzgerald resumed coverage on GH Research PLC with a new price target

      Cantor Fitzgerald resumed coverage of GH Research PLC with a rating of Overweight and set a new price target of $25.00

      6/4/25 8:19:53 AM ET
      $GHRS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Guggenheim initiated coverage on GH Research PLC with a new price target

      Guggenheim initiated coverage of GH Research PLC with a rating of Buy and set a new price target of $32.00

      3/13/25 7:38:21 AM ET
      $GHRS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • RBC Capital Mkts initiated coverage on GH Research PLC with a new price target

      RBC Capital Mkts initiated coverage of GH Research PLC with a rating of Outperform and set a new price target of $31.00

      3/7/25 7:25:01 AM ET
      $GHRS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GHRS
    Financials

    Live finance-specific insights

    See more

    $GHRS
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • GH Research Announces Primary Endpoint Met in Phase 2b Trial with GH001 in TRD Demonstrating -15.5 Point Placebo-adjusted MADRS Reduction

      Primary endpoint met, GH001 led to an ultra-rapid anti-depressant effect with a significant placebo-adjusted MADRS reduction from baseline of -15.5 on Day 8 (p<0.0001)The majority of the patients treated with GH001 achieved remission with a 57.5% remission rate on Day 8 compared with 0% in the placebo group (p<0.0001)All other secondary endpoints were met with clinically and statistically significant improvements on Day 8, compared with placeboDuring the double-blind part, GH001 was well tolerated and no serious adverse events (SAE) were reported. There was no evidence of treatment-emergent suicidal ideation or behavior. As of January 22, 2025, no SAEs have been reported throughout the open

      2/3/25 7:00:10 AM ET
      $GHRS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • GH Research to Provide Update on Phase 2b Trial with GH001 in TRD

      DUBLIN, Jan. 31, 2025 (GLOBE NEWSWIRE) -- GH Research PLC (NASDAQ:GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today announced that it will host a conference call and live webcast on Monday, February 3, 2025, at 8.00 a.m. EST to provide an update on data from the randomized, double-blind, placebo-controlled Phase 2b trial of GH001 in treatment-resistant depression (TRD). To access the conference call, please register in advance here. A live webcast of the call will be available under "Events & Presentations" in the Investors section of GH Research PLC's website at ghres.com. About GH Research PLC GH

      1/31/25 4:01:35 PM ET
      $GHRS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • GH Research Announces Acceptance of Pharmaceutical Pipeline Presentation and Late-Breaking Posters at the American Society of Clinical Psychopharmacology 2025 Annual Meeting

      DUBLIN, May 15, 2025 (GLOBE NEWSWIRE) -- GH Research PLC (NASDAQ:GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment in depression, today announced the acceptance of a Pharmaceutical Pipeline Presentation at the American Society of Clinical Psychopharmacology Annual Meeting (ASCP) in Arizona, United States from May 27 – 30, where Professor Michael E. Thase, MD, Professor of Psychiatry, Perelman School of Medicine, University of Pennsylvania will present clinical data from a randomized, double-blind, placebo-controlled Phase 2b clinical trial with GH001 in patients with treatment-resistant depression (

      5/15/25 7:00:00 AM ET
      $GHRS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • GH Research Reports First Quarter 2025 Financial Results and Provides Business Updates

      Primary endpoint met in Phase 2b trial with GH001 in TRD demonstrating -15.5 Point placebo-adjusted MADRS reductionFull response to the IND hold on track for submission in mid-2025Cash, cash equivalents, other financial assets and marketable securities of $315.3 million as of March 31, 2025 DUBLIN, May 08, 2025 (GLOBE NEWSWIRE) -- GH Research PLC (NASDAQ:GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment in depression, today reported financial results for the quarter ended March 31, 2025, and provided updates on its business. Business Updates GH001 in Patients with TRD Our multi-center, randomize

      5/8/25 7:00:03 AM ET
      $GHRS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • GH Research Reports Full Year 2024 Financial Results and Provides Business Updates

      Phase 2b clinical trial of GH001 in patients with treatment-resistant depression on track for completion of last patient visit in the open-label extension in Q1 2025Phase 1 clinical trial to evaluate proprietary aerosol delivery device in healthy volunteers is ongoing in the UKFull response to the IND hold on track for submission in mid-2025Cash, cash equivalents, other financial assets and marketable securities of $182.6 million as of December 31, 2024Net cash proceeds of an additional $139.8 million from public offering received in February 2025 DUBLIN, Feb. 27, 2025 (GLOBE NEWSWIRE) -- GH Research PLC (NASDAQ:GHRS), a clinical-stage biopharmaceutical company dedicated to transforming t

      2/27/25 7:00:25 AM ET
      $GHRS
      Biotechnology: Pharmaceutical Preparations
      Health Care